Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
58.9M
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
40.7M
-
Shares change
-
+1.15M
-
Total reported value, excl. options
-
$619M
-
Value change
-
+$12.4M
-
Put/Call ratio
-
7.96
-
Number of buys
-
60
-
Number of sells
-
-65
-
Price
-
$15.20
Significant Holders of Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share (VNDA) as of Q4 2017
164 filings reported holding VNDA - Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share as of Q4 2017.
Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share (VNDA) has 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.7M shares
of 58.9M outstanding shares and own 69.14% of the company stock.
Largest 10 shareholders include BlackRock Inc. (4.57M shares), Palo Alto Investors, LLC (4.16M shares), Vanguard Group Inc (2.83M shares), ARMISTICE CAPITAL, LLC (2.68M shares), MACQUARIE GROUP LTD (2.27M shares), STATE STREET CORP (2.14M shares), RENAISSANCE TECHNOLOGIES LLC (1.43M shares), venBio Select Advisor LLC (1.41M shares), ROTHSCHILD ASSET MANAGEMENT INC (1.37M shares), and FMR LLC (1.31M shares).
This table shows the top 124 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.